Loading…
Cardiol Therapeutics Inc. is projected to rise to $1.50 by 2027, a +18% move from its current price of $1.27. CRDL is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.23 | $1.27 | $1.31 | +0.01% |
| Aug 5 | $1.21 | $1.27 | $1.33 | +0.02% |
| Aug 6 | $1.20 | $1.27 | $1.34 | +0.03% |
| Aug 7 | $1.19 | $1.27 | $1.36 | +0.05% |
| Aug 8 | $1.18 | $1.27 | $1.37 | +0.06% |
| Aug 9 | $1.17 | $1.27 | $1.38 | +0.07% |
| Aug 10 | $1.17 | $1.27 | $1.39 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.17 | $1.27 | $1.39 | +0.08% |
| Week 2 | $1.13 | $1.27 | $1.44 | +0.16% |
| Week 3 | $1.10 | $1.27 | $1.48 | +0.24% |
| Week 4 | $1.07 | $1.27 | $1.51 | +0.32% |
| Week 5 | $1.05 | $1.28 | $1.55 | +0.40% |
| Week 6 | $1.03 | $1.28 | $1.58 | +0.48% |
| Week 7 | $1.02 | $1.28 | $1.60 | +0.56% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focusing on anti-fibrotic and anti-inflammatory therapies for heart diseases. Its lead product candidate CardiolRx is in a Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Cardiol Therapeutics Inc. falls within the Healthcare sector and operates as a biotechnology-focused pharmaceutical developer pursuing therapies for heart-related conditions.
Cardiol Therapeutics Inc. (CRDL) currently trades at $1.23 per share and has a market capitalization of $141.78M, placing it among smaller-cap healthcare names with a rank of 3948 by market cap.
The near-term forecast for 2026 shows a neutral stance with a min of $0.926, an average of $1.23, and a max of $1.55, and a 0% return.
Longer-term forecasts depict a clear growth path, with the average price rising from $1.76 by 2030 to $8.30 by 2050, and corresponding ROIs climbing from 43.5% in 2030 to 575.1% in 2050, indicating substantial upside potential over the horizon.
A major floor 29.7% below — a decisive break under it would weaken the trend.
The nearest floor, 21.9% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 28.3% above — clearing it would confirm fresh momentum.
Key CRDL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CRDL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.20 | Buy | $1.22 | Buy |
| MA 10 | $1.21 | Buy | $1.20 | Buy |
| MA 20 | $1.15 | Buy | $1.17 | Buy |
| MA 50 | $1.13 | Buy | $1.16 | Buy |
| MA 100 | $1.21 | Buy | $1.16 | Buy |
| MA 200 | $1.12 | Buy | $1.16 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.02 | Neutral |
| Stoch RSI (14) | 58.98 | Neutral |
| CCI (20) | 100.94 | Buy |
| Williams %R (14) | -5.88 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 14.41 | Buy |
| Bollinger %B (20,2) | 0.82 | Neutral |
| Stochastic %K (14) | 94.12 | Sell |
| TRIX (15) | 0.32 | Buy |
| Awesome (5,34) | 0.09 | Buy |
| Ultimate (7,14,28) | 55.17 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 1.20 | Buy |
| ADX (14) | 21.05 | Buy |
| ATR (14) | 0.04 | Info |
The 30-day technical picture leans bullish in sentiment, with RSI(14) at 70 and moving averages showing near-term support and resistance levels. The 50-day simple moving average sits at $1.16 and the 200-day simple moving average at $1.11, framing a constructive trend.
Key support is identified at $0.992 and resistance at $1.23. The 30-day price range spans from a low of $0.984 to a high of $1.54, providing a defined trading band over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.926 | $1.27 | $1.56 | 0% | Neutral | |
| $1.18 | $1.50 | $2.04 | +18% | Neutral | |
| $1.16 | $1.54 | $2.18 | +21% | Bullish | |
| $1.18 | $1.60 | $2.35 | +26% | Bullish | |
| $1.31 | $1.83 | $2.76 | +44% | Bullish | |
| $1.44 | $2.05 | $3.17 | +62% | Bullish | |
| $1.86 | $2.71 | $4.28 | +113% | Bullish | |
| $2.05 | $3.05 | $4.91 | +140% | Bullish | |
| $1.95 | $2.96 | $4.85 | +133% | Bullish | |
| $2.10 | $3.25 | $5.42 | +156% | Bullish | |
| $3.29 | $5.53 | $9.89 | +335% | Bullish | |
| $4.34 | $8.48 | $16.78 | +568% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.926 | $1.27 | $1.51 | +0.00% |
| September 2026 | $1.07 | $1.27 | $1.56 | +0.30% |
| October 2026 | $1.07 | $1.28 | $1.59 | +0.74% |
| November 2026 | $1.03 | $1.24 | $1.55 | -3.55% |
| December 2026 | $1.01 | $1.23 | $1.56 | -0.68% |
Click any year to see its month-by-month CRDL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CRDL to range from $0.926 to $1.56 through 2026. The $1.27 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CRDL price prediction for 2027 points to an average of $1.50 (low $1.18, high $2.04) — a potential gain of +18% on today's $1.27. A consolidation phase looks the most probable path here.
In 2028, CRDL is projected to trade between $1.16 and $2.18, averaging $1.54 — a potential gain of +21% from today's $1.27. That is up +2% on the projected 2027 average. Momentum favours further upside here.
Cardiol Therapeutics Inc.'s 2029 outlook centres on $1.60, within a $1.18 to $2.35 range. That is up +4% on the projected 2028 average. That marks a +26% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CRDL could reach as high as $2.76, with a base case around $1.83 and support toward $1.31 — roughly +44% from $1.27. Momentum favours further upside here.
Expect CRDL to range from $1.44 to $3.17 through 2031. The $2.05 average target implies a +62% move from current prices. That is up +12% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CRDL price prediction for 2032 points to an average of $2.71 (low $1.86, high $4.28) — a potential gain of +113% on today's $1.27. Momentum favours further upside here.
In 2033, CRDL is projected to trade between $2.05 and $4.91, averaging $3.05 — a potential gain of +140% from today's $1.27. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Cardiol Therapeutics Inc.'s 2034 outlook centres on $2.96, within a $1.95 to $4.85 range. That is -3% versus the projected 2033 average. That marks a +133% change versus current levels. Momentum favours further upside here.
By 2035, CRDL could reach as high as $5.42, with a base case around $3.25 and support toward $2.10 — roughly +156% from $1.27. Buyers look set to stay in control over this stretch.
Expect CRDL to range from $3.29 to $9.89 through 2040. The $5.53 average target implies a +335% move from current prices. That is up +70% on the projected 2035 average. Momentum favours further upside here.
The CRDL price prediction for 2050 points to an average of $8.48 (low $4.34, high $16.78) — a potential gain of +568% on today's $1.27. Buyers look set to stay in control over this stretch.
Investing $1,000 in CRDL today (≈ 787.401575 CRDL) could be worth
$6,678.5
+$5,678.5 (+568%) by 2050 · US Dollar
Based on the average projected CRDL price of $8.48 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CRDLwould be worth at today's price.
$1,000 invested in CRDL on Jul 31, 2025 (≈ 671.140935 CRDL) would be worth
$852.35
-$147.65 (-14.8%) today · 0.85× · US Dollar
Based on a CRDL entry price of $1.49 vs. today's $1.27.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.18 | $1,076.27 | +7.6% |
| 1 month ago | $1.05 | $1,209.52 | +21.0% |
| 3 months ago | $1.37 | $927.01 | -7.3% |
| 6 months ago | $0.961 | $1,321.54 | +32.2% |
| 1 year ago | $1.49 | $852.35 | -14.8% |
| All time (5.0y) ago | $2.15 | $590.7 | -40.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CRDL forecast.
Our base-case forecast reaches $2.50 around 2032.
Implied market cap at $2.50: $288.18M
The multi-year forecast paints a trajectory of expanding value. In 2026, the min, avg, and max are $0.926, $1.23, and $1.55 with an expected 0% ROI and neutral sentiment. By 2027 the avg rises to $1.46 with an 18.7% ROI, and 2028 shows an avg of $1.47 with a 19.2% ROI.
In 2029, the avg is $1.55 (26.3% ROI) and the outlook turns bullish, continuing into 2030 with an avg of $1.76 and a 43.5% ROI. The path remains bullish through 2031 ($1.98 avg, 60.9% ROI) and 2032 ($2.67 avg, 117.3% ROI), then 2033 ($2.93 avg, 138.5% ROI) and 2034 ($2.80 avg, 127.8% ROI).
From 2035 onward, the forecast highlights stronger upside, with 2035 at $3.21 avg (161.3% ROI), and 2040 projecting a $5.26 average with a 327.5% ROI and a max of $9.55. By 2050, the average is $8.30 with a 575.1% ROI and a peak of $16.72, signaling pronounced long-term upside despite inherent uncertainty.
Tap a question to reveal the answer.
For 2030, the forecast lists min $1.25, avg $1.76, max $2.69 with a 43.5% ROI and a bullish sentiment.
Forecasts show positive ROIs in multiple years (e.g., 2027 18.7%, 2028 19.2%, 2029 26.3%, 2030 43.5%, 2031 60.9%, 2032 117.3%, 2033 138.5%, 2034 127.8%, 2035 161.3%, 2040 327.5%, 2050 575.1%), but these are estimates and not guarantees.
The 2040 forecast lists a max of $9.55 and the 2050 forecast lists a max of $16.72, indicating potential to exceed $5, but these projections are not guaranteed.
Current price is $1.23 and market cap is $141.78M.
The 30-day range is from $0.984 to $1.54, with RSI(14) at 70, a 50-day SMA of $1.16, a 200-day SMA of $1.11, and a near-term support at $0.992 and resistance at $1.23.
Cardiol Therapeutics Inc. Community Discussion
0Share your Cardiol Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.